UNSPSC 51292707: Metralindole hydrochloride

This classification denotes an antidepressant agent with the molecular formula C15H17N3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M15TM76Y3L, chemically known as 3-methyl-8-methoxy-3h-1,2,5,6-tetrahydropyrazino(1,2,3-a,b)-.beta.-carboline hydrochloride, but more generally known as metralindole hydrochloride, which bears US NIH Compound Identifier 171296. European Medicines Agency schedules metralindole hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08915MIG.

Most nations, for tariff purposes, schedule metralindole hydrochloride under HS 29335995. SMILES: CN1CCN2C3CCC(CC3C4C2C1=NCC4)OC.CL.

UNSPSC 51292707 Metralindole hydrochloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health systems, though the code's nominal scope diverges from what is actually being solicited. The recent opportunities tagged to this code include naloxone (an opioid antagonist), safe drug deactivation systems, multi-source generic pharmaceuticals, and over-the-counter products — none of which are metralindole hydrochloride specifically. State and local buyers using this code are county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Issuing bodies range from individual county procurement offices to statewide purchasing consortia serving multiple jurisdictions, with repeat activity from state-level pharmaceutical procurement programs.

Activity is geographically dispersed across Florida, Texas, Minnesota, and Oregon, with representation from county-level health procurement in Florida, state HHS commissions in Texas, and multistate cooperative purchasing through the Minnesota Department of Administration. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson. The code shows minimal recent activity directly aligned to metralindole hydrochloride procurement, suggesting either coding misalignment by the issuing bodies or limited state and local demand for this specific pharmaceutical.